Daclatasvir is a new medication approved by US FDA to treat Hepatitis C. It’s a research product of Bristol Myer Squibb and marketed in the brand name Daklinza.Beacon Pharmaceuticals Ltd is the 1^st global company to introduce copy of Daklinza in the brand name Daclavir. Considering the affordibility of global patient we have offered the product at a very affordable price, which costs 160 time lesser price than originator brand. Full treatment cost by our brand is only US$ 384,where as cost by originator  is $ 6300-said Mr.  Karim , Managing Director of Beacon.

Hepatitis C is a viral disease that causes inflammation of the liver that lead to diminished liver function or liver failure. Globally, about 170-185 million population are chronically infected with Hepatitis C virus. In Bangladesh, Hepatitis emerges as a major health problem with nearly 2 million people is infected by Hepatitis virus. The US FDA approved the use of Daclatasvir together with another novel Hep C drugs, sofosbuvir for the treatment Hepatitis.